Scholarly Index
Eric K. Rowinsky
CTI BioPharma (Italy); 40,933 total citations; 444 total publications; best world rank #14
CTI BioPharma (Italy)
40,933Total citations
444Total publications
89H-index
Published ranking records
| Field | Window | World rank | National rank | Impact score |
|---|---|---|---|---|
| Cancer therapeutics and mechanisms | Lifetime | 25 | IT 1 | 99.72 |
| Cancer Treatment and Pharmacology | Lifetime | 55 | IT 4 | 99.78 |
| Neutropenia and Cancer Infections | Lifetime | 37 | IT 3 | 99.50 |
| Chemotherapy-related skin toxicity | Lifetime | 14 | IT 1 | 99.06 |
| Lung Cancer Research Studies | Lifetime | 133 | IT 9 | 99.41 |
| Colorectal Cancer Treatments and Studies | Lifetime | 169 | IT 15 | 99.40 |
| Lung Cancer Treatments and Mutations | Lifetime | 282 | IT 19 | 99.27 |
| HER2/EGFR in Cancer Research | Lifetime | 139 | IT 10 | 99.33 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 156 | IT 6 | 98.56 |
| Microtubule and mitosis dynamics | Lifetime | 408 | IT 3 | 97.27 |
| Multiple Myeloma Research and Treatments | Lifetime | 765 | IT 67 | 96.38 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 406 | IT 38 | 92.89 |
| Cancer Mechanisms and Therapy | Lifetime | 962 | IT 43 | 91.81 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 831 | IT 21 | 79.48 |